转化为简体中文并保留原句结构：对于有转移性肾细胞癌（mRCC）和肿瘤栓的患者而言，预后依旧不佳。最近的数据表明细胞减灭肾（CN）的作用有限，而关于栓对全身治疗（ST）的反应的数据很少。在这里，我们描述了接受ST治疗（有或无CN）的新患mRCC和栓的患者的反应和生存情况。收集了新患mRCC的人口统计学、疾病特征和生存情况。使用Kaplan-Meier方法（对数排名）计算了无进展生存期（PFS）和总生存期（OS）（以月为单位）。在2002年至2019年间，识别了226例患有mRCC的患者，其中64例（28.3%）有肿瘤栓，其中18例（28.1%）只接受了ST。在12例可评价的患者中，有3例（25%）出现了栓的反应，6例（50%）保持稳定，3例（25%）出现了进展。与仅接受全身治疗的无肿瘤栓的患者相比，具有肿瘤栓的患者的中位总生存期相似[OS：12.1 m（8.8-27.7）与13.9 m（7.9-21.5），p = 0.87]。CN预示着肿瘤栓患者的更好的OS [OS：29.4 m（17.4-48.9）与12.1 m（8.8-27.7），p = 0.01]。在这个回顾性系列研究中，为mRCC和肿瘤栓患者添加CN可以改善结果。需要使用现代方案验证这些发现。©2023.作者。

Outcomes for patients with metastatic renal cell carcinoma (mRCC) and tumour thrombus remain poor. Recent data suggest limited role for cytoreductive nephrectomy (CN) and data on thrombus response to systemic therapy (ST) is scarce. Here, we describe response and survival of patients with de novo mRCC and thrombi treated with ST with or without CN.Demographics, disease characteristics and survival of patients with de novo mRCC were collected. Progression-free survival (PFS) and overall survival (OS) in months (m) was calculated using the Kaplan-Meier method (log-rank).Between 2002 and 2019, 226 patients with mRCC were identified, 64 (28.3%) had tumour thrombus out of which 18 (28.1%) received only ST. Among 12 evaluable patients, thrombus response, stability and progression were seen in 3 (25%), 6 (50%) and 3 (25%) patients, respectively. Median OS was similar for patients with and without tumour thrombus treated with systemic therapy alone [OS: 12.1 m (8.8-27.7) vs. 13.9 m (7.9-21.5), p = 0.87]. CN predicted for better OS in patients with tumour thrombus [OS: 29.4 m (17.4-48.9) vs. 12.1 m (8.8-27.7), p = 0.01].In this retrospective series of patients with mRCC and tumour thrombus, addition of CN to ST improved outcomes. Validation of these findings with contemporary regimens is needed.© 2023. The Author(s).